Ligand Pharmaceuticals Inc
LGNXZ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 8 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $6.34B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $17.0M in total
- 8
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $268.1M
- +60.4% year over year
- Net income, FY2025
- $124.5M
- No comparable prior period
- Free cash flow, FY2025
- $48.9M
- −48.6% year over year
- Revenue, Q3 FY2026
- $78.7M
- −31.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Superinvestors holding LGNXZ, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding LGNXZ at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ligand Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 (view filing)5:41 PM ET | Nov 4 | 2 days | Aryeh JasonDirector | SSale | −282 | $319.99 | −$90.2K | −0.3%108.5K after | |
| Nov 4, 2026 (view filing)4:23 PM ET | Nov 2 | 2 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $313.22 | −$1.57M | −13.6%31.9K after | 13 lots10b5-1 |
| Nov 3, 2026 (view filing)7:39 PM ET | Oct 30-Nov 2 | 4 days | Aryeh JasonDirector | SSale | −2.11K | $320.30 | −$676.2K | −1.9%108.8K after | 6 lots |
| Oct 6, 2026 (view filing)4:35 PM ET | Oct 2 | 4 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $304.07 | −$1.52M | −13.6%31.9K after | 6 lots10b5-1 |
| Sep 14, 2026 (view filing)4:59 PM ET | Sep 10 | 4 days | Zimmermann MartineDirector | SSale | −1.20K | $285.00 | −$342.0K | −23.5%3.90K after | |
| Sep 8, 2026 (view filing)6:34 PM ET | Sep 3 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $286.09 | −$1.43M | −12.0%36.5K after | 5 lots10b5-1 |
| Aug 14, 2026 (view filing)5:05 PM ET | Aug 12 | 2 days | Espinoza OctavioChief Financial Officer | SSale | −31.6K | $292.07 | −$9.24M | −53.3%27.7K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:04 PM ET | Aug 12 | 2 days | Haas JasonDirector | SSale | −7.14K | $292.81 | −$2.09M | −64.2%3.98K after | |
| Aug 4, 2026 (view filing)6:42 PM ET | Aug 3 | 1 day | Reardon AndrewCLO & Secretary | SSale | −5.00K | $288.99 | −$1.44M | −10.7%41.5K after | 10 lots10b5-1 |
| Jul 6, 2026 (view filing)5:11 PM ET | Jul 1 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $313.28 | −$1.57M | −10.7%41.5K after | 8 lots10b5-1 |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Ligand Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding LGNXZ in 13F filings for Q2 2026.
Politician trades
All politician trades in LGNXZ2 members of Congress reported 8 trades in Ligand Pharmaceuticals Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Jun 8, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Apr 7, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Feb 13, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Feb 13, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Dec 3, 2020 |  Katherine M. Clark House · MA | Sell | $1K-$15K |
House · CA · Jun 8, 2026
Buy$1K-$15K
House · CA · Apr 7, 2026
Buy$1K-$15K
House · CA · Feb 13, 2026
Buy$1K-$15K
House · CA · Feb 13, 2026
Buy$1K-$15K
House · MA · Dec 3, 2020
Sell$1K-$15K